Email Page Print Page

BEMA® Technology


The BEMA drug delivery technology consists of a small, bioerodible polymer film for application to the mucosal membranes (inner lining of cheek). BEMA films were designed to rapidly deliver a dose of drug across the mucous membranes for time sensitive conditions or to facilitate administration of drugs with poor oral (pill) absorption.


BEMA films are designed to:


  • Adhere to oral mucosa in less than 5 seconds
  • Optimize delivery across the oral mucosa
  • Completely dissolve


The first product to be developed and marketed using the BEMA technology was Onsolis (fentanyl buccal soluble film). Following the successful development and approval of the first product utilizing the BEMA technology, we began to apply the same technology to improve the delivery of other therapies, such as buprenorphine and buprenorphine/naloxone.  The BEMA technology may also be developed with other active drugs, particularly in conditions where rapid delivery of drug is important, oral dosing is not optimal, or where intravenous line or injections are unavailable or not practical.  BDSI owns the worldwide rights to the BEMA drug delivery technology.




Get the latest details on our products and services.

Top News

BioDelivery Sciences Announces Additions to its Board of Directors
Timothy C. Tyson joins BDSI's board as an independent member with over 30 years of pharmaceutical experience

BioDelivery Sciences Cites Impressive Number of Physicians Granted Waiver to Increase Patient Limit for Opioid Dependence Treatment Following Recent HHS Rule
SAMHSA Reports 1,665 Clinicians Granted Waivers at the Increased Limit as of This Week

BioDelivery Sciences to Present at the Ladenburg Thalmann 2016 Healthcare Conference

BioDelivery Sciences Announces Three New Managed Care Agreements; Further Enhancing Access to BUNAVAIL
New contracts improve BUNAVAIL formulary status and give BUNAVAIL access to approximately 200,000 additional prescriptions for buprenorphine products for opioid dependence annually

BioDelivery Sciences to Present at the Rodman & Renshaw 18th Annual Global Investment Conference and the 7th Annual Credit Suisse Small and Mid Cap Conference